Table 1 |
||||
|
Selected characteristics of the study population |
||||
| Characteristic |
Cases (n = 220) |
Controls (n = 570) |
||
|
|
||||
| Matched variables |
||||
| Age at diagnosis (years) |
||||
| <40 |
17 |
(8%) |
23 |
(4%) |
| 40–49 |
42 |
(19%) |
127 |
(22%) |
| 50–59 |
64 |
(29%) |
152 |
(27%) |
| 60–74 |
97 |
(44%) |
268 |
(47%) |
| Race/ethnicity |
||||
| White, non-Hispanic |
172 |
(78%) |
457 |
(80%) |
| White, Hispanic |
7 |
(3%) |
13 |
(2%) |
| Black |
20 |
(9%) |
47 |
(8%) |
| Asian |
21 |
(10%) |
53 |
(9%) |
| Surgery year |
||||
| 1985–1989 |
146 |
(66%) |
385 |
(68%) |
| 1990–1994 |
74 |
(34%) |
185 |
(32%) |
| Adjuvant tamoxifen |
||||
| No |
156 |
(71%) |
393 |
(69%) |
| Yes |
64 |
(29%) |
177 |
(31%) |
| Unmatched variables |
||||
| ER status from RT-PCR1 |
||||
| Positive |
168 |
(76%) |
514 |
(90%) |
| Negative |
52 |
(24%) |
56 |
(10%) |
| Tumor size (cm) |
||||
| ≤1 |
49 |
(22%) |
193 |
(34%) |
| 1.1–2 |
93 |
(42%) |
255 |
(45%) |
| 2.1–4 |
72 |
(33%) |
114 |
(20%) |
| >4 |
6 |
(3%) |
8 |
(1%) |
| Tumor grade (differentiation)2 |
||||
| Well |
25 |
(11%) |
175 |
(31%) |
| Moderate |
92 |
(42%) |
261 |
(46%) |
| Poor |
103 |
(47%) |
134 |
(23%) |
| Recurrence Score |
||||
| Low risk (<18) |
57 |
(26%) |
322 |
(56%) |
| Intermediate risk (18–30) |
54 |
(25%) |
108 |
(19%) |
| High risk (≥31) |
109 |
(50%) |
140 |
(25%) |
|
|
||||
|
1Cutoff points based on RT-PCR values: ≤6.5 and >6.5 units. 2Bloom-Richardson grading criteria, pathologist 1. ER, estrogen receptor; RT-PCR, reverse transcription polymerase chain reaction. |
||||
|
Habel et al. Breast Cancer Research 2006 8:R25 doi:10.1186/bcr1412 |
||||
